Effect of citrullus colocynthis on Type II diabetes

The effect of citrullus colocynthis fruit extract on blood sugar in type II diabetic patients: a double blind clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013010211984N1

Enrollment

Registered

2014-07-03

Start date

2012-12-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Citrullus colocynthis capsule 100mg/TDS for 4 months. Intervention 2: Placebo capsule100mg/TDS for 4 months.

Treatment - Drugs

Placebo

Citrullus colocynthis capsule 100mg/TDS for 4 months

Placebo capsule100mg/TDS for 4 months

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 30 to 60 years; fasting blood glucose between 180-220 mg/dl; HbA1c 7.5-9%; taking two metformin 500 mg or two glibenclamid 5 mg tablets daily; with minimum two year history of diabetes that not changed antidiabetic regimen before 3 months. Exclusion criteria:Insulin therapy; severe kidney, liver, cardiovascular and infectious disease; pregnant and breast feeding woman.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood sugar. Timepoint: At baseline and after four months. Method of measurement: Fasting blood glucose was measured by commercial kit in laboratory.;Glycosylated haemoglobin. Timepoint: At baseline and after four months. Method of measurement: Blood HbA1C was determined in laboratory by commercially available kit.	—

Secondary

Measure	Time frame
LDL. Timepoint: At baseline and after four months. Method of measurement: Blood LDL level was determined in laboratory by commercially available kit.;HDL. Timepoint: At baseline and after four months. Method of measurement: Blood HDL level was determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At baseline and after four months. Method of measurement: Blood cholesterol level was determined in laboratory by commercially available kit.;Triglyceride. Timepoint: At baseline and after four months. Method of measurement: Blood triglyceride level was determined in laboratory by commercially available kit.;AST (aspartate aminotransferase). Timepoint: At baseline and after four months. Method of measurement: Blood AST level was determined in laboratory by commercially available kit.;ALT (alanine aminotransferase). Timepoint: At baseline and after four months. Method of measurement: Blood ALT level was determined in laboratory by commercially available kit.;Creatinine. Timepoint: At baseline and after four months. Method of measurement: Blood creatinine level was determined in laboratory by commercially available kit.	—

Measure

Time frame

LDL. Timepoint: At baseline and after four months. Method of measurement: Blood LDL level was determined in laboratory by commercially available kit.;HDL. Timepoint: At baseline and after four months. Method of measurement: Blood HDL level was determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At baseline and after four months. Method of measurement: Blood cholesterol level was determined in laboratory by commercially available kit.;Triglyceride. Timepoint: At baseline and after four months. Method of measurement: Blood triglyceride level was determined in laboratory by commercially available kit.;AST (aspartate aminotransferase). Timepoint: At baseline and after four months. Method of measurement: Blood AST level was determined in laboratory by commercially available kit.;ALT (alanine aminotransferase). Timepoint: At baseline and after four months. Method of measurement: Blood ALT level was determined in laboratory by commercially available kit.;Creatinine. Timepoint: At baseline and after four months. Method of measurement: Blood creatinine level was determined in laboratory by commercially available kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Yaghoobi

Zahedan University of Medical Sciences

yaghoobi@zaums.ac.ir+98 54 1244 2482

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026